Cargando…
Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature
BACKGROUND: Pancreatic cancer (PC) is a highly lethal malignancy, even if surgical resection is possible (median survival: < 30 months). The prognosis of borderline resectable pancreatic cancer (BR-PC) is even worse. There is no clear consensus on the optimal treatment strategy, including pre/pos...
Autores principales: | Kinoshita, Mitsuru, Watanabe, Sota, Mizojiri, Gaku, Sada, Akitada, Kai, Hiroki, Masuike, Yasunori, Nagasawa, Yoshinobu, Maruyama, Kentaro, Lee, Kyowon, Ohata, Mai, Ishikawa, Osamu, Oka, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9474757/ https://www.ncbi.nlm.nih.gov/pubmed/36103018 http://dx.doi.org/10.1186/s40792-022-01529-z |
Ejemplares similares
-
Fluorescence cholangiography for detection of a cystic duct drained into an accessory hepatic duct: A case report
por: Kinoshita, Mitsuru, et al.
Publicado: (2022) -
A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer
por: Okano, Naohiro, et al.
Publicado: (2022) -
Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
por: Tsujimoto, Akiko, et al.
Publicado: (2019) -
Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
por: Ingram, Myles A., et al.
Publicado: (2022) -
Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis
por: Damm, Marko, et al.
Publicado: (2021)